Tricuspid Valve Regurgitation – Comprehensive Medical Guide

Overview

Tricuspid valve regurgitation (TR), also called tricuspid insufficiency, occurs when the tricuspid valve does not close tightly during right‑ventricular contraction, allowing blood to leak backward from the right ventricle into the right atrium. The tricuspid valve sits between the right atrium and right ventricle and normally functions like a one‑way gate, ensuring blood moves forward through the lungs for oxygenation.

TR can be primary (organic)—caused by disease of the valve itself—or secondary (functional), which results from dilation of the right ventricle or atrium due to other cardiac conditions.

Who is affected?

• Adults over 60 years old are most commonly diagnosed; prevalence rises steeply after age 70.
• Both sexes are affected, but some studies show a slight predominance in women.
• Patients with left‑sided heart disease, pulmonary hypertension, or a history of cardiac surgery have a higher risk.

Prevalence

According to the American Heart Association, mild TR is present in up to 65 % of echocardiograms performed on older adults, while clinically significant (moderate‑to‑severe) TR occurs in about 0.5‑1 % of the general population. In patients with chronic left‑sided heart failure, the prevalence of moderate‑to‑severe TR can exceed 15 % ¹.

Symptoms

Many people with mild TR are asymptomatic. Symptoms usually appear when regurgitation becomes moderate to severe, or when it is accompanied by other cardiac or pulmonary conditions.

Common Symptoms

• Fatigue & reduced exercise tolerance – the heart must work harder to pump the same amount of blood.
• Shortness of breath (dyspnea) – especially on exertion or when lying flat (orthopnea).
• Swelling (edema) – typically in the ankles, feet, or abdomen (ascites) as blood backs up in the systemic circulation.
• Abdominal discomfort or fullness – from liver congestion (congestive hepatopathy).
• Visible neck veins (jugular venous distention) – a classic sign of increased right‑atrial pressure.
• Palpitations – irregular heartbeat can develop from atrial enlargement.
• Weight gain – rapid weight gain of several pounds over days signals fluid accumulation.

Less Common or Late‑Stage Symptoms

• Chest pain – usually due to concurrent coronary artery disease.
• Syncope or near‑syncope – from low cardiac output.
• Hepatomegaly and tender liver edge.
• Bleeding from esophageal varices – rare, occurs when severe liver congestion leads to portal hypertension.

Causes and Risk Factors

TR is categorized as primary or secondary.

Primary (Organic) Causes

• Infective endocarditis – bacterial infection damages valve leaflets.
• Rheumatic heart disease – scarring from prior rheumatic fever.
• Congenital malformations – e.g., Ebstein anomaly.
• Trauma or iatrogenic injury – from pacemaker leads, central venous catheters, or cardiac surgery.
• Carcinoid syndrome – serotonin‑rich tumors produce plaque‑like deposits on the valve.

Secondary (Functional) Causes

• Left‑sided heart failure – elevated pressures transmit backward to the right side.
• Pulmonary hypertension – high pressure in pulmonary arteries stresses the right ventricle.
• Right‑ventricular dilation – from chronic volume overload (e.g., atrial septal defect).
• Severe tricuspid annular dilation – often seen in patients with chronic atrial fibrillation.

Risk Factors

• Age > 60 years.
• History of left‑sided valve disease (mitral or aortic).
• Chronic lung disease (COPD, interstitial lung disease).
• Obstructive sleep apnea.
• Persistent atrial fibrillation.
• Prior cardiac surgery involving the tricuspid valve.
• Intravenous drug use (raises risk of infective endocarditis).

Diagnosis

Diagnosis combines clinical assessment with imaging and, occasionally, hemodynamic testing.

Physical Examination

• Holosystolic murmur best heard at the left lower sternal border, accentuated during inspiration (Carvallo’s sign).
• Elevated jugular venous pressure, liver pulsation, peripheral edema.

Imaging & Tests

• Transthoracic echocardiography (TTE) – first‑line; evaluates severity (vena contracta width, regurgitant volume), right‑ventricular size, and pressures.
• Transesophageal echocardiography (TEE) – provides superior visualization of valve anatomy, useful before surgery.
• Cardiac MRI – accurate quantification of right‑ventricular function and regurgitant volume when echo windows are poor.
• CT angiography – assesses annular dimensions for procedural planning.
• Right‑heart catheterization – measures pulmonary artery pressure and cardiac output; reserved for complex cases or before valve intervention.
• Electrocardiogram (ECG) – may show atrial fibrillation, right‑bundle branch block, or signs of right‑ventricular hypertrophy.
• Blood tests – BNP/NT‑proBNP (marker of heart failure), liver function tests (to detect congestion), CBC, and cultures if infection is suspected.

Grading Severity

Guidelines from the American Society of Echocardiography define mild, moderate, and severe TR based on jet area, vena contracta, hepatic vein flow reversal, and quantitative regurgitant volume. Severe TR is typically ≥ 45 mL regurgitant volume per beat or a regurgitant fraction ≥ 50 %.

Treatment Options

Therapy is individualized, focusing on symptom relief, halting disease progression, and addressing underlying causes.

Medical Management

• Diuretics (e.g., furosemide, torsemide) – reduce systemic congestion and peripheral edema.
• Guideline‑directed therapy for left‑sided heart failure – ACE inhibitors/ARBs, beta‑blockers, mineralocorticoid receptor antagonists.
• Pulmonary vasodilators (e.g., phosphodiesterase‑5 inhibitors) when pulmonary hypertension is a major driver.
• Anti‑arrhythmic drugs or rate control for atrial fibrillation (beta‑blockers, digoxin, anticoagulation as indicated).
• Antibiotic prophylaxis – only for patients with prosthetic tricuspid valves undergoing certain dental or respiratory procedures.

Interventional & Surgical Options

1. Transcatheter Tricuspid Valve Repair (TTVR) – devices such as edge‑to‑edge clips (MitraClip XT) or annular reduction systems (TriClip, Cardioband) are FDA‑approved for patients deemed high‑risk for surgery.
2. Transcatheter Tricuspid Valve Replacement (TTVR) – newer valve-in-valve or heterotopic valves for severe regurgitation when repair is not feasible.
3. Surgical Tricuspid Valve Repair – annuloplasty rings or De‑Vega suture techniques; preferred when the patient is already undergoing left‑sided surgery.
4. Surgical Tricuspid Valve Replacement – bioprosthetic or mechanical valves; reserved for structurally damaged leaflets or when repair is impossible.

Decision‑making incorporates symptom burden, right‑ventricular function, comorbidities, and surgical risk scores (e.g., STS‑PROM, EuroSCORE II).

Lifestyle & Self‑Care

• Low‑sodium diet (≤ 2 g Na⁺/day) to curb fluid retention.
• Fluid restriction (1.5‑2 L/day) if instructed by a heart‑failure specialist.
• Regular, moderate‑intensity aerobic activity (e.g., walking) as tolerated; avoid high‑intensity or isometric exercises that sharply raise intrathoracic pressure.
• Weight monitoring – daily weigh‑ins to detect rapid fluid gain.
• Vaccinations (influenza, pneumococcal, COVID‑19) to reduce respiratory infections that could exacerbate pulmonary pressures.

Living with Tricuspid Valve Regurgitation

Adapting daily life while maintaining quality of life involves practical strategies.

Monitoring & Follow‑Up

• Clinic visits every 6‑12 months if stable; sooner if symptoms change.
• Repeat echocardiogram annually (or sooner if clinical change) to assess progression.
• Home blood pressure and heart‑rate logs; aim for BP < 130/80 mmHg unless otherwise directed.

Managing Fatigue

1. Prioritize tasks; break activities into short bouts with rest.
2. Plan outings earlier in the day when energy levels are higher.
3. Consider assistive devices (e.g., handrails, raised toilet seats) to conserve energy.

Dealing with Edema

• Elevate legs above heart level for 15‑30 minutes, 3–4 times daily.
• Wear graduated compression stockings (20‑30 mmHg) unless contraindicated.
• Consult your provider before adding over‑the‑counter diuretics.

Psychosocial Support

Chronic cardiac disease can lead to anxiety or depression. Access counseling, support groups, or cardiac rehabilitation programs. The American Heart Association offers online patient communities for valve disease.

Prevention

While you cannot change the fact that valve tissue ages, many modifiable factors lower the risk of developing severe TR.

• Control blood pressure and cholesterol – reduces left‑sided heart disease and subsequent right‑sided overload.
• Quit smoking – improves pulmonary vasculature and lowers pulmonary hypertension risk.
• Maintain healthy weight – obesity predisposes to obstructive sleep apnea and pulmonary hypertension.
• Manage sleep apnea – CPAP therapy helps lower right‑ventricular pressures.
• Prompt treatment of respiratory infections – reduces acute spikes in pulmonary pressures.
• Safe intravenous practices – avoid non‑sterile injections to prevent infective endocarditis.

Complications

If left untreated, moderate‑to‑severe TR can lead to a cascade of complications.

• Right‑sided heart failure – marked systemic congestion, ascites, and hepatic dysfunction.
• Severe hepatic congestion – “cardiac cirrhosis” with elevated bilirubin and coagulopathy.
• Atrial fibrillation – due to atrial dilation; increases stroke risk.
• Renal dysfunction – low forward cardiac output and venous congestion impair kidney perfusion.
• Cardiac cachexia – progressive muscle wasting from chronic heart failure.
• Increased mortality – observational studies link severe TR with a 2‑3‑fold higher 5‑year mortality compared with patients without TR, independent of other risk factors².

When to Seek Emergency Care

---

References:
1. American Heart Association. “Heart Disease and Stroke Statistics—2024 Update.” Circulation. 2024.
2. Dreyfus GD, et al. “Prognostic impact of severe tricuspid regurgitation in heart failure.” JACC: Heart Failure. 2022;10(5):382‑391.
3. Mayo Clinic. “Tricuspid valve regurgitation.” Accessed May 2026.
4. National Institutes of Health, National Heart, Lung, and Blood Institute. “Valvular Heart Disease.” 2023.
5. European Society of Cardiology. “Guidelines for the management of valvular heart disease.” 2021.